ClinicalTrials.gg
CompletedNCT01344369Updated May 30, 2011Results posted

Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions

A Phase 1 interventional study of Norethindrone/Ethinyl Estradiol and FEMCON® Fe in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-05-30.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The purpose of this study was to evaluate the relative bioavailability of a test formulation of norethindrone/ethinyl estradiol 0.4 mg/0.035 mg chewable tablets (Teva Pharmaceuticals, USA) compared to the reference listed product, FEMCON® Fe (norethindrone/ethinyl estradiol and ferrous fumarate) 0.4 mg/0.035 mg Chewable tablets (Warner Chilcott) under fed conditions in healthy, non-tobacco using, adult female subjects.

02

Conditions studied

  • Healthy

Keywords

  • Healthy Subjects
  • Bioequivalence
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females, 18-45 years of age inclusive with within 18-30 kg/m2 inclusive, as described in Novum Standard Operating Procedures. Female subjects must either abstain from sexual intercourse or use a reliable non-hormonal method of (e.g. condom with spermicide, diaphragm, non-hormonal IUD) from at least 14 days prior to the first study dosing, throughout the study, and until 14 days after the last dose.
  • Normal menstrual cycle.
  • Good health as determined by lack of abnormalities in health assessments performed at screening.
  • Signed and dated form, which meets all criteria of current FDA regulations.

Exclusion criteria

Exclusion Criteria:

  • Post menopausal or have irregular menstrual cycle.
  • Pregnant, lactating, or likely to become pregnant during the study.
  • History of any drug or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the study.
  • Significant history or current evidence of chronic infectious disease, system disorder, or organ dysfunction.
  • Presence of gastrointestinal disease or history of malabsorption within the last year.
  • History of psychiatric disorders occurring within the last two years that required hospitalization or medication.
  • Presence of a medical condition requiring regular treatment with prescription drugs.
  • Use of pharmacologic agents known to significantly induce or inhibit drug-metabolizing enzymes within 30 days prior to dosing.
  • Participation in any clinical trial within 30 days prior to dosing.
  • Drug or alcohol addiction requiring treatment in the past 12 months.
  • Donation or significant loss of whole blood (480 mL or more) within 30 days or plasma within 14 days prior to dosing.
  • Positive test results for , surface antigen, or antibody.
  • Positive test results for drugs of abuse at screening.
  • Positive serum pregnancy test.
  • Subjects who have ever had progestational hormone implants.
  • Subjects who have had progestational hormone depot injections within 12 months proceeding dosing.
  • Subjects who are using or have used within the 3 months preceding dosing any vaginally administered estrogen or progestin-containing products.
  • Any personal or strong family history of estrogen- or progestogen-dependent tumors.
  • History of fibrocystic breast disease.
  • Subjects with a history of thromboembolic disorders, myocardial infarction, or stroke.
  • Use of norethindrone or ethinyl estrodiol-containing oral within 30 days of initial dosing.
  • Hysterectomy or oophorectomy (unilateral or bilateral)
  • User of tobacco or nicotine containing products within 30 days of the start of the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Investigational Test Product

    Norethindrone/Ethinyl Estradiol 0.4 mg/0.035 mg Chewable Tablets (Teva)

    Drug: Norethindrone/Ethinyl Estradiol

  • Active comparator
    Reference Listed Drug

    FEMCON® Fe 0.4 mg/0.035 mg Chewable tablets (Warner Chilcott)

    Drug: FEMCON® Fe

Interventions

  • DrugNorethindrone/Ethinyl Estradiol

    Drug pages: Norethindrone · Ethinyl Estradiol

    0.4 mg/0.035 mg Chewable Tablets

    Also known as: Zeosa®

  • DrugFEMCON® Fe

    0.4 mg/0.035 mg Chewable Tablets

    Also known as: Ovcon® 35 Fe, norethindrone/ethinyl estradiol (generic name)

06

What researchers measure

Primary outcomes

  1. Cmax of Norethindrone

    Bioequivalence based on Norethindrone Cmax (maximum observed concentration of drug substance in plasma).

    Time frame: Blood samples collected over a 60 hour period.

  2. AUC0-t of Norethindrone

    Bioequivalence based on Norethindrone AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).

    Time frame: Blood samples collected over a 60 hour period.

  3. AUC0-inf of Norethindrone

    Bioequivalence based on Norethindrone AUC0-inf (area under the concentration-time curve from time zero to infinity).

    Time frame: Blood samples collected over a 60 hour period.

  4. Cmax of Ethinyl Estradiol

    Bioequivalence based on Ethinyl Estradiol Cmax (maximum observed concentration of drug substance in plasma).

    Time frame: Blood samples collected over a 60 hour period.

  5. AUC0-t of Ethinyl Estradiol

    Bioequivalence based on Ethinyl Estradiol AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).

    Time frame: Blood samples collected over a 60 hour period.

  6. AUC0-inf of Ethinyl Estradiol

    Bioequivalence based on Ethinyl Estradiol AUC0-inf (area under the concentration-time curve from time zero to infinity).

    Time frame: Blood samples collected over a 60 hour period.

07

Results

Posted May 30, 2011

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneNorethindrone/Ethinyl Estradiol (Test) FirstFEMCON® Fe (Reference) First
Started1818
Completed1818
Not completed00
Washout of 28 Days
Participant flow — Washout of 28 Days
MilestoneNorethindrone/Ethinyl Estradiol (Test) FirstFEMCON® Fe (Reference) First
Started1818
Completed1717
Not completed11
Withdrew: Withdrawal by subject10
Withdrew: Physician decision01
Second Intervention
Participant flow — Second Intervention
MilestoneNorethindrone/Ethinyl Estradiol (Test) FirstFEMCON® Fe (Reference) First
Started1717
Completed1716
Not completed01
Withdrew: Emesis within 2 x tmax01

Outcome measures

PrimaryCmax of Norethindrone

Bioequivalence based on Norethindrone Cmax (maximum observed concentration of drug substance in plasma).

Time frame:
Blood samples collected over a 60 hour period.
Reported as:
Mean · ng/mL
Cmax of Norethindrone
ng/mLNorethindrone/Ethinyl Estradiol (Test)FEMCON® Fe (Reference)
Cmax of Norethindrone4.3306 ± 1.73934.2282 ± 1.6696
Statistical analysis
  • Norethindrone/Ethinyl Estradiol (Test) vs FEMCON® Fe (Reference) · Ratio of the t/r geometric mean x 100: 102.44 · 90% CI 93.08 to 112.75Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.
PrimaryAUC0-t of Norethindrone

Bioequivalence based on Norethindrone AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).

Time frame:
Blood samples collected over a 60 hour period.
Reported as:
Mean · ng*h/mL
AUC0-t of Norethindrone
ng*h/mLNorethindrone/Ethinyl Estradiol (Test)FEMCON® Fe (Reference)
AUC0-t of Norethindrone37.8065 ± 16.192137.3991 ± 15.3939
Statistical analysis
  • Norethindrone/Ethinyl Estradiol (Test) vs FEMCON® Fe (Reference) · Ratio of the t/r geometric mean x 100: 100.58 · 90% CI 96.66 to 104.66Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.
PrimaryAUC0-inf of Norethindrone

Bioequivalence based on Norethindrone AUC0-inf (area under the concentration-time curve from time zero to infinity).

Time frame:
Blood samples collected over a 60 hour period.
Reported as:
Mean · ng*h/mL
AUC0-inf of Norethindrone
ng*h/mLNorethindrone/Ethinyl Estradiol (Test)FEMCON® Fe (Reference)
AUC0-inf of Norethindrone43.9982 ± 19.455943.8819 ± 18.8478
Statistical analysis
  • Norethindrone/Ethinyl Estradiol (Test) vs FEMCON® Fe (Reference) · Ratio of the t/r geometric mean x 100: 100.85 · 90% CI 96.43 to 105.48Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.
PrimaryCmax of Ethinyl Estradiol

Bioequivalence based on Ethinyl Estradiol Cmax (maximum observed concentration of drug substance in plasma).

Time frame:
Blood samples collected over a 60 hour period.
Reported as:
Mean · pg/mL
Cmax of Ethinyl Estradiol
pg/mLNorethindrone/Ethinyl Estradiol (Test)FEMCON® Fe (Reference)
Cmax of Ethinyl Estradiol137.6758 ± 33.6231137.8485 ± 37.6177
Statistical analysis
  • Norethindrone/Ethinyl Estradiol (Test) vs FEMCON® Fe (Reference) · Ratio of the t/r geometric mean x 100: 100.59 · 90% CI 93.69 to 108.00Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.
PrimaryAUC0-t of Ethinyl Estradiol

Bioequivalence based on Ethinyl Estradiol AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).

Time frame:
Blood samples collected over a 60 hour period.
Reported as:
Mean · pg*h/mL
AUC0-t of Ethinyl Estradiol
pg*h/mLNorethindrone/Ethinyl Estradiol (Test)FEMCON® Fe (Reference)
AUC0-t of Ethinyl Estradiol1916.2311 ± 433.48751987.6311 ± 478.7842
Statistical analysis
  • Norethindrone/Ethinyl Estradiol (Test) vs FEMCON® Fe (Reference) · Ratio of the t/r geometric mean x 100: 96.68 · 90% CI 92.76 to 100.77Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.
PrimaryAUC0-inf of Ethinyl Estradiol

Bioequivalence based on Ethinyl Estradiol AUC0-inf (area under the concentration-time curve from time zero to infinity).

Time frame:
Blood samples collected over a 60 hour period.
Reported as:
Mean · pg*h/mL
AUC0-inf of Ethinyl Estradiol
pg*h/mLNorethindrone/Ethinyl Estradiol (Test)FEMCON® Fe (Reference)
AUC0-inf of Ethinyl Estradiol2072.5423 ± 483.01762152.3775 ± 517.5977
Statistical analysis
  • Norethindrone/Ethinyl Estradiol (Test) vs FEMCON® Fe (Reference) · Ratio of the t/r geometric mean x 100: 96.44 · 90% CI 92.22 to 100.84Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.

Adverse events

Collected over Adverse event data was collected over the course of the study, which was approximately 6 weeks in duration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Norethindrone/Ethinyl Estradiol (Test)—0/36 (0%)13/36 (36.1%)
FEMCON® Fe (Reference)—0/36 (0%)10/36 (27.8%)
Most frequent other events
Most frequent other events
EventNorethindrone/Ethinyl Estradiol (Test)FEMCON® Fe (Reference)
NauseaGeneral disorders6/363/36
VomitingGeneral disorders5/363/36
HeadacheGeneral disorders5/361/36
Abdominal CrampingGeneral disorders4/360/36
Sinus CongestionGeneral disorders0/362/36
Decreased Blood PressureGeneral disorders2/362/36
Increased TemperatureGeneral disorders0/362/36
Increased Blood PressureGeneral disorders1/362/36

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Norethindrone/Ethinyl Estradiol (Test) FirstFEMCON® Fe (Reference) FirstTotal
<=18 years000
Between 18 and 65 years181836
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Norethindrone/Ethinyl Estradiol (Test) FirstFEMCON® Fe (Reference) FirstTotal
Female181836
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Norethindrone/Ethinyl Estradiol (Test) FirstFEMCON® Fe (Reference) FirstTotal
Black121426
Caucasian213
Hispanic437
Region of Enrollment
Region of Enrollment(participants)Norethindrone/Ethinyl Estradiol (Test) FirstFEMCON® Fe (Reference) FirstTotal
United States181836
08

Study locations

1 site
  • Novum Pharmaceutical Research Services
    Houston, Texas 77042-4712, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2011
First posted
Apr 29, 2011
Start
Aug 2008
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
May 30, 2011
Last update
May 30, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01344369
First posted
Apr 29, 2011
Start date
Aug 2008
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
May 30, 2011
Last update
May 30, 2011

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Norethindrone · Ethinyl Estradiol

Start the discussion